CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--Emisphere Technologies, Inc. (OTC BB: EMIS) today announced the publication of an article in the September issue of Clinical Pharmacology and Therapeutics, that describes previously reported findings of an independent clinical study designed to assess the pharmacokinetics, pharmacodynamics (PK/PD) and safety of oral administration of the peptide GLP-1 utilizing Emisphere’s Eligen® carrier technology.
